High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis

Cai,Hongyu; Shao,Bingfeng; Zhou,Yuan; Chen,Zhong

doi:10.3892/ol.2020.12095

High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis

Authors:
- Hongyu Cai
- Bingfeng Shao
- Yuan Zhou
- Zhong Chen
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu 226361, P.R. China, Department of General Surgery, The First Affiliated Hospital of Soochow University, Soochow, Jiangsu 215006, P.R. China
Published online on: September 11, 2020 https://doi.org/10.3892/ol.2020.12095
Article Number: 232
Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is a common malignant tumor in the clinic. Although there are increasing numbers of available treatment methods, their therapeutic effects are not satisfactory. The clinical indicators commonly used to predict the prognosis of HCC include tumor size, degree of cirrhosis, degree of tumor differentiation and tumor microvascular invasion; however, there are currently no molecular indicators that can predict the prognosis of HCC. Due to the differences in the progression of liver cancer among individuals, there is a growing need for prognostic biomarkers to accurately stratify patients for appropriate risk‑adaptive treatment. The DNA topoisomerase 2‑α (TOP2A) gene, which is located on human chromosome 17, encodes DNA topoisomerase IIα. Previous studies have demonstrated that TOP2A indicates a poor prognosis in patients with various types of tumors, but no such studies are currently available on HCC. By analyzing the differential expression of TOP2A in 50 pairs of tumor and paracancerous tissue samples in The Cancer Genome Atlas (TCGA) database, the present study revealed that the expression of TOP2A was significantly higher in tumor tissue compared with that in paracancerous tissue (P=6.319x10‑16). In the collected clinical samples, the mRNA expression levels of TOP2A were significantly upregulated in HCC tumor tissues compared with those in the paracancerous tissues (P=6.40x10‑3), suggesting that TOP2A was associated with the occurrence and development of liver cancer. In addition, the associations between TOP2A expression, clinicopathological features and prognosis were analyzed using a multi‑center large sample dataset from TCGA database, and the results demonstrated that high expression of TOP2A was associated with a higher T stage, poorer clinical stage and higher histological grade compared with those in patients with low TOP2A expression. High expression of TOP2A was also identified to be associated with a poor prognosis of HCC, particularly in Asian populations. These results suggested that high expression of TOP2A in HCC tissues may be closely associated with tumor progression and metastasis, which may be used as a biological indicator to predict tumor prognosis in clinical practice.

View Figures

View References

1	WHO: Cancer today. https://gco.iarc.fr/today/homeJune 24–2019
2	Daher S, Massarwa M, Benson AA and Khoury T: Current and future treatment of hepatocellular carcinoma: An updated comprehensive review. J Clin Transl Hepatol. 6:69–78. 2018. View Article : Google Scholar : PubMed/NCBI
3	Park SJ, Jang JY, Jeong SW, Cho YK, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, et al: Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. Medicine (Baltimore). 96:e58112017. View Article : Google Scholar : PubMed/NCBI
4	Sharma SA, Kowgier M, Hansen BE, Brouwer WP, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote EJ, et al: Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J Hepatol. Aug 24–2017.(Epub ahead of print). doi: 10.1016/j.jhep.2017.07.033.
5	Shen J, He L, Li C, Wen T, Chen W, Lu C, Yan L, Li B and Yang J: Nomograms to predict the individual survival of patients with solitary hepatocellular carcinoma after hepatectomy. Gut Liver. 11:684–692. 2017. View Article : Google Scholar : PubMed/NCBI
6	Visone V, Vettone A, Serpe M, Valenti A, Perugino G, Rossi M and Ciaramella M: Chromatin structure and dynamics in hot environments: Architectural proteins and DNA topoisomerases of thermophilic archaea. Int J Mol Sci. 15:17162–17187. 2014. View Article : Google Scholar : PubMed/NCBI
7	Choi IY, Chung IK and Muller MT: Eukaryotic topoisomerase II cleavage is independent of duplex DNA conformation. Biochim Biophys Acta. 1264:209–214. 1995. View Article : Google Scholar : PubMed/NCBI
8	Austin CA, Lee KC, Swan RL, Khazeem MM, Manville CM, Cridland P, Treumann A, Porter A, Morris NJ and Cowell IG: TOP2B: The first thirty years. Int J Mol Sci. 19:27652018. View Article : Google Scholar
9	Bush NG, Evans-Roberts K and Maxwell A: DNA topoisomerases. EcoSal Plus. 6:2015. View Article : Google Scholar : PubMed/NCBI
10	Antoniou-Kourounioti M, Mimmack ML, Porter ACG and Farr CJ: The impact of the C-terminal region on the interaction of topoisomerase II alpha with mitotic chromatin. Int J Mol Sci. 20:12382019. View Article : Google Scholar
11	Demoulin B, Hermant M, Castrogiovanni C, Staudt C and Dumont P: Resveratrol induces DNA damage in colon cancer cells by poisoning topoisomerase II and activates the ATM kinase to trigger p53-dependent apoptosis. Toxicol In Vitro. 29:1156–1165. 2015. View Article : Google Scholar : PubMed/NCBI
12	Sudan S and Rupasinghe HPV: Flavonoid-enriched apple fraction AF4 induces cell cycle arrest, DNA topoisomerase II inhibition, and apoptosis in human liver cancer HepG2 cells. Nutr Cancer. 66:1237–1246. 2014. View Article : Google Scholar : PubMed/NCBI
13	Kania EE, Carvajal-Moreno J, Hernandez VA, English A, Papa JL, Shkolnikov N, Ozer HG, Yilmaz AS, Yalowich JC and Elton TS: hsa-miR-9-3p and hsa-miR-9-5p as post-transcriptional modulators of DNA topoisomerase IIα in human leukemia K562 cells with acquired resistance to etoposide. Mol Pharmacol. 97:159–170. 2020. View Article : Google Scholar : PubMed/NCBI
14	Kanagasabai R, Karmahapatra S, Kientz CA, Yu Y, Hernandez VA, Kania EE, Yalowich JC and Elton TS: The novel c-terminal truncated 90-kDa isoform of topoisomerase IIα (TOP2α/90) is a determinant of etoposide resistance in K562 leukemia cells via heterodimerization with the TOP2α/170 isoform. Mol Pharmacol. 93:515–525. 2018. View Article : Google Scholar : PubMed/NCBI
15	D Arcy N and Gabrielli B: Topoisomerase II inhibitors and poisons, and the influence of cell cycle checkpoints. Curr Med Chem. 24:1504–1519. 2017.PubMed/NCBI
16	Wang JC: Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol. 3:430–440. 2002. View Article : Google Scholar : PubMed/NCBI
17	Jain CK, Roychoudhury S and Majumder HK: Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor. Biochim Biophys Acta. 1853:1195–1204. 2015. View Article : Google Scholar : PubMed/NCBI
18	Deng SP and Guo WL: Identifying key genes of liver cancer by networking of multiple data sets. IEEE/ACM Trans Comput Biol Bioinform. 16:792–800. 2019. View Article : Google Scholar
19	Yu Y, Ding S, Liang Y, Zheng Y, Li W, Yang L, Zheng X and Jiang J: Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis. Exp Ther Med. 7:1578–1582. 2014. View Article : Google Scholar : PubMed/NCBI
20	Xing C, Cai Z, Gong J, Zhou J, Xu J and Guo F: Identification of potential biomarkers involved in gastric cancer through integrated analysis of non-coding RNA associated competing endogenous RNAs network. Clin Lab. 64:1661–1669. 2018. View Article : Google Scholar : PubMed/NCBI
21	Liu LM, Xiong DD, Lin P, Yang H, Dang YW and Chen G: DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride. Int J Oncol. 53:1897–1912. 2018.PubMed/NCBI
22	Eltohamy MI, Badawy OM, El kinaai N, Loay I, Nassar HR, Allam RM and Ali Sakr M: Topoisomerase II α gene alteration in triple negative breast cancer and its predictive role for anthracycline-based chemotherapy (Egyptian NCI Patients). Asian Pac J Cancer Prev. 19:3581–3589. 2018. View Article : Google Scholar : PubMed/NCBI
23	Wittmann S, Wunder C, Zirn B, Furtwängler R, Wegert J, Graf N and Gessler M: New prognostic markers revealed by evaluation of genes correlated with clinical parameters in wilms tumors. Genes Chromosomes Cancer. 47:386–395. 2008. View Article : Google Scholar : PubMed/NCBI
24	Xu XL, Zheng WH, Fu ZX, Li ZP, Xie HX, Li XX, Jiang LH, Wang Y, Zhu SM and Mao WM: Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas. Med Oncol. 32:3962015. View Article : Google Scholar : PubMed/NCBI
25	de Resende MF, Vieira S, Chinen LT, Chiappelli F, da Fonseca FP, Guimarães GC, Soares FA, Neves I, Pagotty S, Pellionisz PA, et al: Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med. 11:362013. View Article : Google Scholar : PubMed/NCBI
26	Şahin S, Gönül II, Çakır A, Seçkin S and Uluoğlu O: Clinicopathological significance of the proliferation markers Ki67, RacGAP1, and topoisomerase 2 alpha in breast cancer. Int J Surg Pathol. 24:607–613. 2016. View Article : Google Scholar : PubMed/NCBI
27	Pei YF, Yin XM and Liu XQ: TOP2A induces malignant character of pancreatic cancer through activating β-catenin signaling pathway. Biochim Biophys Acta Mol Basis Dis. 1864:197–207. 2018. View Article : Google Scholar : PubMed/NCBI
28	Labbe DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, et al: TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clin Cancer Res. 23:7072–7083. 2017. View Article : Google Scholar : PubMed/NCBI
29	Villman K, Sjöström J, Heikkilä R, Hultborn R, Malmström P, Bengtsson NO, Söderberg M, Saksela E and Blomqvist C: TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncol. 45:590–596. 2006. View Article : Google Scholar : PubMed/NCBI
30	Ito F, Furukawa N and Nakai T: Evaluation of TOP2A as a predictive marker for endometrial cancer with taxane-containing adjuvant chemotherapy. Int J Gynecol Cancer. 26:325–330. 2016. View Article : Google Scholar : PubMed/NCBI
31	Roca E, Berruti A, Sbiera S, Rapa I, Oneda E, Sperone P, Ronchi CL, Ferrari L, Grisanti S, Germano A, et al: Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer. Endocr Relat Cancer. 24:319–327. 2017. View Article : Google Scholar : PubMed/NCBI
32	Cai HY, Zhu XH, Qian F, Shao B, Zhou Y, Zhang Y and Chen Z: High expression of TOP2A gene predicted poor prognosis of hepatocellular carcinoma after radical hepatectomy. Transl Cancer Res. 9:983–992. 2020. View Article : Google Scholar
33	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
34	R Core Team (2014): R, . A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: http://www.R-project.org/
35	Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e472015. View Article : Google Scholar : PubMed/NCBI
36	Ecklund A: beeswarm: The Bee Swarm Plot, an Alternative to Stripchart. https://CRAN.R-project.org/package=beeswarm
37	Kulik L and El-Serag HB: Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 156:477–491 e471. 2019. View Article : Google Scholar : PubMed/NCBI
38	Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, et al: Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. J Hepatol. 71:543–552. 2019. View Article : Google Scholar : PubMed/NCBI
39	Di Bisceglie AM and Hoofnagle JH: Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer. 64:2117–2120. 1989. View Article : Google Scholar : PubMed/NCBI
40	Agopian VG, Harlander-Locke MP, Markovic D, Zarrinpar A, Kaldas FM, Cheng EY, Yersiz H, Farmer DG, Hiatt JR and Busuttil RW: Evaluation of patients with hepatocellular carcinomas that do not produce α-fetoprotein. JAMA Surg. 152:55–64. 2017. View Article : Google Scholar : PubMed/NCBI
41	Luo P, Wu S, Yu Y, Ming X, Li S, Zuo X and Tu J: Current status and perspective biomarkers in AFP negative HCC: Towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Pathol Oncol Res. 26:599–603. 2020. View Article : Google Scholar : PubMed/NCBI
42	European Association For The Study Of The Liver; European Organisation For Research and Treatment Of Cancer, . EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI
43	Yan L, Xu F and Dai C: Overexpression of COL24A1 in hepatocellular carcinoma predicts poor prognosis: A study based on multiple databases, clinical samples and cell lines. Onco Targets Ther. 13:2819–2832. 2020. View Article : Google Scholar : PubMed/NCBI
44	Luo YD, Yu HQ, Liu XY, Huang D, Dai HS, Fang L, Zhang YJ, Lai JJ, Jiang Y, Shuai L, et al: Prognostic and predicted significance of Ubqln2 in patients with hepatocellular carcinoma. Cancer Med. 9:4083–4094. 2020. View Article : Google Scholar : PubMed/NCBI
45	Chen L, Liu D, Yi X, Qi L, Tian X, Sun B, Dong Q, Han Z, Li Q, Song T, et al: The novel miR-1269b-regulated protein SVEP1 induces hepatocellular carcinoma proliferation and metastasis likely through the PI3K/Akt pathway. Cell Death Dis. 11:3202020. View Article : Google Scholar : PubMed/NCBI
46	Chen J, Ding C, Chen Y, Hu W, Lu Y, Wu W, Zhang Y, Yang B, Wu H, Peng C, et al: ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK/FBW7/c-Myc axis. Oncogenesis. 9:422020. View Article : Google Scholar : PubMed/NCBI
47	Zhao X, Chen Y, Mao Q, Jiang X, Jiang W, Chen J, Xu W, Zhong L and Sun X: Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Biomark. 21:859–868. 2018. View Article : Google Scholar : PubMed/NCBI
48	Li F, Bai L, Li S, Chen Y, Xue X and Yu Z: Construction and evaluation of a prognosis lncRNA model for hepatocellular carcinoma. J Cell Biochem. Apr 29–2020.(Epub ahead of print). doi: https://doi.org/10.1002/jcb.29608.
49	Kou F, Sun H, Wu L, Li B, Zhang B, Wang X and Yang L: TOP2A promotes lung adenocarcinoma cells' malignant progression and predicts poor prognosis in lung adenocarcinoma. J Cancer. 11:2496–2508. 2020. View Article : Google Scholar : PubMed/NCBI
50	Liu T, Zhang H, Yi S, Gu L and Zhou M: Mutual regulation of MDM4 and TOP2A in cancer cell proliferation. Mol Oncol. 13:1047–1058. 2019. View Article : Google Scholar : PubMed/NCBI
51	Zeng S, Liu A, Dai L, Yu X, Zhang Z, Xiong Q, Yang J, Liu F, Xu J, Xue Y, et al: Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms. BMC Cancer. 19:6042019. View Article : Google Scholar : PubMed/NCBI
52	Badawy OM and Loay I: FISH analysis of TOP2A and HER-2 aberrations in female breast carcinoma on archived material: Egyptian NCI experience. Appl Immunohistochem Mol Morphol. 27:216–222. 2019. View Article : Google Scholar : PubMed/NCBI
53	Zhang R, Xu J, Zhao J and Bai JH: Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2A. J Cell Biochem. 119:7256–7263. 2018. View Article : Google Scholar : PubMed/NCBI
54	Xiong Y, Yuan L, Chen L, Zhu Y, Zhang S, Liu X, Xiao Y and Wang X: Identifying a novel biomarker TOP2A of clear cell renal cell carcinoma (ccRCC) associated with smoking by co-expression network analysis. J Cancer. 9:3912–3922. 2018. View Article : Google Scholar : PubMed/NCBI
55	Nelson WG, Haffner MC and Yegnasubramanian S: The structure of the nucleus in normal and neoplastic prostate cells: Untangling the role of type 2 DNA topoisomerases. Am J Clin Exp Urol. 6:107–113. 2018.PubMed/NCBI
56	Panvichian R, Tantiwetrueangdet A, Angkathunyakul N and Leelaudomlipi S: TOP2A amplification and overexpression in hepatocellular carcinoma tissues. Biomed Res Int. 2015:3816022015. View Article : Google Scholar : PubMed/NCBI
57	Ng IO, Na J, Lai EC, Fan ST and Ng M: Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1. A comparison with proliferating cell nuclear antigen. Am J Clin Pathol. 104:313–318. 1995. View Article : Google Scholar : PubMed/NCBI
58	Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY). 3:192–222. 2011. View Article : Google Scholar : PubMed/NCBI
59	Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu C, Liu D, Zheng M, Sun J, Feng H and Lu A: Tumor-derived CXCL5 promotes human colorectal cancer metastasis through activation of the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways. Mol Cancer. 16:702017. View Article : Google Scholar : PubMed/NCBI
60	Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, et al: African American specific gene panel predictive of poor prostate cancer outcome. J Urol. 202:247–255. 2019. View Article : Google Scholar : PubMed/NCBI
61	Rocha-Singh KJ: Retrospective real-world studies of paclitaxel and mortality: Defining the many faces of bias. JACC Cardiovasc Interv. May 14–2020.(Epub ahead of print). doi: 10.1016/j.jcin.2020.05.006. View Article : Google Scholar : PubMed/NCBI